Try EntheoIM!
Your payment is protected
Your donation is being processed
Please do not resubmit. This page will update automatically once your donation is confirmed.
Thank You for Supporting Entheology Project
Project:
Amount:
Type:
We sincerely appreciate your generous donation to Entheology Project Inc. As a 501(c)(3) public charity (EIN 88-1953133), your donation is tax-deductible to the extent allowed by law. You will receive an email confirmation for your records, which can be used for tax purposes. Your support helps us continue our mission and make a meaningful impact!
Return to Support a Project | Share This Project
Best Regards,
EP Support
help@entheologyproject.org
We could not complete your donation.
No payment was recorded. Please review your payment information or try another method.
Eli Lilly’s aquires AtaiBeckley for $3.8 billion
By Rev
This is a watershed moment for psychedelic medicine.
Eli Lilly’s acquisition of AtaiBeckley for up to $3.8 billion sends a strong signal that psychedelic therapeutics are moving from the margins toward mainstream pharmaceutical development. The deal centers on BPL-003, an intranasal synthetic 5-MeO-DMT candidate for treatment-resistant depression that is advancing into Phase 3.
But this milestone also raises important questions.
As capital and large pharmaceutical companies enter the space, how do we preserve the principles that many believe are essential to these therapies—patient preparation, appropriate support, integration, ethical access, and responsible use?
Scientific validation and broader access are important. So is ensuring that commercialization doesn’t overshadow the human elements that contribute to safe and effective care.
The future of psychedelic medicine won’t be defined solely by breakthrough molecules. It will also be defined by the systems, ethics, and standards we build around them.
What do you think this means for the future of psychedelic-assisted care?
[DISPLAY_ULTIMATE_SOCIAL_ICONS]